Introducing Mi~Scan®
The New Standard for breast tissue composition analysis
(Coming Soon - The Mi~Scan® device is currently undergoing its first clinical trial/s and is expected to be available for order from October (in Europe) with shipments following receipt of European regulatory approval, in early 2025)
Mi~Scan® uses safe, non-ionising radio waves to quickly measure and then analyse breast tissue properties.
The device does not require breast compression and can be used as frequently as required, in both diagnostic and primary care settings.
Know your breast density.
The ratio of fibro-glandular tissue to other tissues, in your breast, can have a significant impact on the ability for a standard Mammogram to detect cancer.
Whilst the amount of fibro-glandular tissue typically reduces with age (particularly post menopause), women of all ages can have “dense” breasts.
The good news is that other techniques, are available, that have much higher sensitivity and specificity in “dense” breasts.
It’s impossible to know your breast “density” through look and feel alone and even interpretation from a Mammogram, can be subjective.
The initial Mi~Scan® product can quickly measure breast density, resulting in the ability to have the best test for detecting cancer, for your personal breast tissue type, first time.
The more the Mi~Scan® device is used, the deeper the insight (we will be able to provide) into breast tissue properties.
Our ultimate goal is for the device to be used to assess breast cancer risk for all women, in the community, quickly, safely, comfortably and as frequently as required.
— Adrian Waller (Micrima CEO)